Clinicopathological features of malignant lymphoma in Miyagi study
| Project/Area Number |
24590677
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUKUHARA Noriko 東北大学, 大学病院, 講師 (10534167)
ISHIZAWA Kenichi 山形大学, 大学院医学系研究科, 教授 (00359506)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 悪性リンパ腫 / 疫学 |
|---|
| Outline of Final Research Achievements |
A total of 3,043 cases of newly diagnosed malignant lymphoma in Miyagi between 2002 and 2012 were enrolled in this epidemiological study. The rate of each subtype was mostly similar to that in our previous report. The most frequent subtype of B-cell lymphoma was diffuse large B-cell lymphoma (DLBCL), followed by follicular lymphoma and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (38.6%, 19.7% and 7.5%).
To identify the biological prognostic factors in DLBCL, we analyzed biological parameters (BCL2, BCL6, c-MYC and BACH2). In cases with high BACH2 expression in GCB (38 cases) and non-GCB groups (38 cases), the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256). In the DLBCL with MYC translocation (n=18), expression of BACH2 may be a prognostic marker (3y OS 75.0% vs 22.9%, P=0.132). BACH2, a B cell-specific transcriptional repressor, may plays a significant role in B cell lymphoma.
|
Report
(4 results)
Research Products
(56 results)
-
-
-
-
-
[Journal Article] Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.2014
Author(s)
Ichikawa, S., Fukuhara, N., Katsushima, H., Takahashi, T., Yamamoto, J., Yokoyama, H., Sasaki, O., Fukuhara, O., Nomura, J., Ishizawa, K., Ichinohasama, R., Muto, A., Igarashi, K., and Harigae, H.
-
Journal Title
Cancer Science
Volume: in press
Issue: 4
Pages: 437-444
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Clonal heterogeneity of lymphoid malignancies correlates with poor prognosis.2014
Author(s)
Suguro M, Yoshida N, Umino A, Kato H, Tagawa H, Nakagawa M, Fukuhara N, Karnan S, Takeuchi I, Hocking TD, Arita K, Karube K, Tsuzuki S, Nakamura S, Kinoshita T, Seto M.
-
Journal Title
Cancer Sci.
Volume: 105
Issue: 7
Pages: 897-904
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.2014
Author(s)
Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS.
-
Journal Title
Br J Haematol
Volume: 165
Issue: 6
Pages: 768-776
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.2014
Author(s)
Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R.
-
Journal Title
J Clin Oncol
Volume: 32
Issue: 11
Pages: 1157-1163
DOI
Related Report
Peer Reviewed
-
[Journal Article] Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.2014
Author(s)
Yamaguchi M, Takata K, Yoshino T, Ishizuka N, Oguchi M, Kobayashi Y, Isobe Y, Ishizawa K, Kubota N, Itoh K, Usui N, Miyazaki K, Wasada I, Nakamura S, Matsuno Y, Oshimi K, Kinoshita T, Tsukasaki K, Tobinai K.
-
Journal Title
Cancer Sci
Volume: 105
Issue: 11
Pages: 1435-1441
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
[Journal Article] Clinicopathological analysis of primary adrenal diffuse large b-cell lymphoma : Effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis2013
Author(s)
Ichikawa S, Fukuhara N, Inoue A, Katsushima H, Ohba R, Katsuoka Y, Onishi Y, Yamamoto J, Sasaki O, Nomura J, Fukuhara O, Ishizawa K, Ichinohasama R, Harigae H
-
Journal Title
Exp Hematol Oncol
Volume: 2
Issue: 1
Pages: 19-19
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Journal Article] Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma2012
Author(s)
Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O, Murai K, Noji H, Hirokawa M, Tajima K, Shichishima T, Ishida Y, Harigae H, Sawada K
-
Journal Title
Int J Hematol
Volume: 96(5)
Issue: 5
Pages: 624-630
DOI
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 腫瘍崩壊症候群の治療2014
Author(s)
石澤賢一
Organizer
日本臨床腫瘍学会
Place of Presentation
福岡国際会議場（福岡市）
Year and Date
2014-07-17 – 2014-07-19
Related Report
Invited
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
